Regenxbio Inc (RGNX)
Profitability ratios
Return on sales
| Dec 31, 2023 | Sep 30, 2023 | Jun 30, 2023 | Mar 31, 2023 | Dec 31, 2022 | Sep 30, 2022 | Jun 30, 2022 | Mar 31, 2022 | Dec 31, 2021 | Sep 30, 2021 | Jun 30, 2021 | Mar 31, 2021 | Dec 31, 2020 | Sep 30, 2020 | Jun 30, 2020 | Mar 31, 2020 | Dec 31, 2019 | Sep 30, 2019 | Jun 30, 2019 | Mar 31, 2019 | |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Gross profit margin | -61.19% | -53.72% | -64.45% | -52.43% | -63.78% | 62.59% | 63.68% | 65.66% | 70.17% | 17.52% | 59.37% | 61.98% | 63.49% | 63.33% | 26.72% | 8.77% | -30.31% | 25.67% | 11.24% | 52.10% |
| Operating profit margin | -313.29% | -292.52% | -323.64% | -286.87% | -293.81% | 27.41% | 28.78% | 30.61% | 35.82% | -153.83% | -49.37% | -45.94% | -43.98% | -40.51% | -163.46% | -211.93% | -335.47% | -144.67% | -169.66% | -57.28% |
| Pretax margin | -308.05% | -290.94% | -331.03% | -301.14% | -313.41% | 21.98% | 24.52% | 26.48% | 31.63% | -153.39% | -50.64% | -42.48% | -39.11% | -36.10% | -144.73% | -147.89% | -219.18% | -85.21% | -88.08% | -37.11% |
| Net profit margin | -307.87% | -290.89% | -330.97% | -301.09% | -313.31% | 18.61% | 21.37% | 23.39% | 28.62% | -157.65% | -52.73% | -44.39% | -41.04% | -34.99% | -141.52% | -144.12% | -213.29% | -87.11% | -88.57% | -41.99% |
Regenxbio Inc's profitability ratios reflect varying levels of performance over the past eight quarters.
The gross profit margin has shown some fluctuations, ranging from a low of 51.61% in Q4 2022 to a high of 61.71% in Q3 2023. Generally, the company has maintained a relatively healthy gross profit margin, indicating efficient management of production costs.
However, the operating profit margin, pretax margin, and net profit margin have all consistently been negative during the periods analyzed. This suggests that the company's operating expenses, including research and development costs, administrative expenses, and potentially non-recurring charges, have exceeded its operating income and net income.
The significant negative values for these margins in recent quarters highlight the challenges faced by Regenxbio Inc in generating profits from its operations. Further analysis would be needed to understand the specific factors driving these losses and whether they are temporary or indicative of broader issues.
In conclusion, while the company has been able to maintain a reasonable gross profit margin, its operational profitability remains a concern as reflected by the consistently negative operating profit margin, pretax margin, and net profit margin figures.
Return on investment
| Dec 31, 2023 | Sep 30, 2023 | Jun 30, 2023 | Mar 31, 2023 | Dec 31, 2022 | Sep 30, 2022 | Jun 30, 2022 | Mar 31, 2022 | Dec 31, 2021 | Sep 30, 2021 | Jun 30, 2021 | Mar 31, 2021 | Dec 31, 2020 | Sep 30, 2020 | Jun 30, 2020 | Mar 31, 2020 | Dec 31, 2019 | Sep 30, 2019 | Jun 30, 2019 | Mar 31, 2019 | |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Operating return on assets (Operating ROA) | -46.71% | -41.34% | -39.28% | -34.43% | -31.55% | 12.28% | 12.82% | 12.92% | 14.36% | -25.90% | -16.26% | -14.28% | -16.84% | -19.57% | -34.63% | -32.50% | -29.92% | -20.86% | -17.59% | -9.60% |
| Return on assets (ROA) | -45.91% | -41.11% | -40.17% | -36.14% | -33.64% | 8.33% | 9.51% | 9.88% | 11.48% | -26.54% | -17.36% | -13.80% | -15.71% | -16.90% | -29.98% | -22.10% | -19.03% | -12.56% | -9.18% | -7.04% |
| Return on total capital | -86.01% | -71.58% | -65.16% | -54.32% | -49.82% | 19.94% | 20.66% | 20.35% | 21.92% | -43.36% | -26.50% | -22.54% | -31.56% | -25.48% | -39.15% | -35.89% | -33.10% | -22.68% | -18.81% | -10.23% |
| Return on equity (ROE) | -84.52% | -71.75% | -67.55% | -58.11% | -54.31% | 13.06% | 14.39% | 14.68% | 16.73% | -46.04% | -28.63% | -21.88% | -29.45% | -22.01% | -33.89% | -24.41% | -21.04% | -13.66% | -9.82% | -7.50% |
Regenxbio Inc's profitability ratios show a downward trend in Q4 2023 compared to the previous quarters. The operating return on assets (Operating ROA) decreased from -31.55% in Q4 2022 to -46.71% in Q4 2023, indicating a decrease in the company's ability to generate profit from its assets through core operations. The Return on assets (ROA) also declined from 8.33% in Q4 2022 to -45.91% in Q4 2023, suggesting a significant decrease in the company's overall profitability.
Furthermore, the Return on total capital and Return on equity (ROE) ratios also deteriorated in Q4 2023. The Return on total capital decreased from 19.24% in Q4 2022 to -86.01% in Q4 2023, reflecting a severe decline in the company's ability to generate profit from its total invested capital. Similarly, the Return on equity (ROE) ratio decreased from 13.06% in Q4 2022 to -84.52% in Q4 2023, indicating a sharp decrease in the company's profitability in relation to shareholders' equity.
Overall, the decreasing trend in profitability ratios for Regenxbio Inc in Q4 2023 suggests potential challenges in generating profits from its assets and maintaining shareholder value. Investors and stakeholders may need to closely monitor the company's financial performance and strategies to address the declining profitability.